Verastem (VSTM) Projected to Post Quarterly Earnings on Wednesday

Verastem (NASDAQ:VSTM) will likely be issuing its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $16.8510 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

Verastem Stock Performance

Shares of NASDAQ VSTM opened at $5.72 on Monday. Verastem has a 1 year low of $4.01 and a 1 year high of $11.24. The stock has a market cap of $381.98 million, a P/E ratio of -1.42 and a beta of 0.40. The firm has a 50-day moving average of $6.69 and a 200 day moving average of $8.25. The company has a debt-to-equity ratio of 2.06, a current ratio of 2.58 and a quick ratio of 2.55.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Verastem in a research note on Wednesday, January 21st. Mizuho set a $18.00 price objective on Verastem in a research report on Thursday, February 19th. Guggenheim reissued a “buy” rating on shares of Verastem in a report on Tuesday, December 30th. HC Wainwright started coverage on Verastem in a research note on Wednesday, February 4th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, Wall Street Zen lowered Verastem from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.33.

Insiders Place Their Bets

In related news, CEO Dan Paterson sold 10,321 shares of Verastem stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $7.16, for a total value of $73,898.36. Following the completion of the sale, the chief executive officer directly owned 400,104 shares in the company, valued at approximately $2,864,744.64. This trade represents a 2.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daniel Calkins sold 5,039 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $7.16, for a total transaction of $36,079.24. Following the transaction, the chief financial officer owned 104,719 shares in the company, valued at $749,788.04. This represents a 4.59% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 25,678 shares of company stock valued at $211,045. Corporate insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Invesco Ltd. lifted its holdings in Verastem by 40.0% in the second quarter. Invesco Ltd. now owns 52,063 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 14,879 shares during the period. Virtus Investment Advisers LLC bought a new stake in shares of Verastem during the 4th quarter valued at about $214,000. Quarry LP purchased a new stake in shares of Verastem during the 4th quarter valued at about $208,000. Graham Capital Management L.P. bought a new position in shares of Verastem in the 4th quarter worth approximately $181,000. Finally, Entropy Technologies LP purchased a new position in shares of Verastem in the fourth quarter worth approximately $161,000. 88.37% of the stock is owned by hedge funds and other institutional investors.

Verastem Company Profile

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.